Goldman Sachs
ASND icon

Goldman Sachs’s Ascendis Pharma A/S ASND Stock Holding History

Goldman Sachs’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50,000
Closed -$5.36M – 5738
2023
Q1 		$5.36M Buy
+50,000
New +$5.72M ﹤0.01% 3002
2020
Q4 		– Sell
-20,000
Closed -$3.09M – 5472
2020
Q3 		$3.09M Buy
+20,000
New +$2.87M ﹤0.01% 3262

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs's ASND Position: Q1 2026 in Review

Goldman Sachs reduced its Ascendis Pharma A/S (ASND) stake by 5.1% in Q1 2026, selling an estimated $6.84M and leaving 566,192 shares worth $130M. The position accounts for 0.01% of the portfolio, ranked #886.

Goldman Sachs first reported a position in ASND in Q4 2017 and has held it in 34 quarters since. The position peaked at $308M in Q2 2022. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Goldman Sachs held 566,192 shares of Ascendis Pharma A/S worth $130M as of Q1 2026.
  • Goldman Sachs sold 30,511 Ascendis Pharma A/S shares in Q1 2026, an estimated $6.84M.
  • Ascendis Pharma A/S made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #886 holding.
  • Goldman Sachs first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 34 quarters since.
  • Goldman Sachs's Ascendis Pharma A/S position peaked at $308M in Q2 2022.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.